CG Oncology (CGON) CFO awarded 90,574 stock options grant

Rhea-AI Filing Summary

CG Oncology, Inc. reported that Chief Financial Officer James M. Detore received an employee stock option grant covering 90,574 shares of common stock. The option has an exercise price of $67.68 per share and expires on April 14, 2036.

According to the vesting terms, the option vests over four years starting on April 15, 2026, with 25% of the shares vesting 12 months after that date and the remaining 75% vesting in 36 equal monthly installments over the following three years. This is a compensation-related award rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider DETORE JAMES M.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	90,574	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 90,574 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 90,574 shares Exercise price: $67.68 per share Expiration date: April 14, 2036 +3 more

6 metrics

Option grant size 90,574 shares Employee stock option award to CFO

Exercise price $67.68 per share Stock option strike price

Expiration date April 14, 2036 Option term end date

Vesting commencement April 15, 2026 Start of vesting schedule

Cliff vesting portion 25% of shares Vests 12 months after commencement

Remainder vesting period 36 monthly installments Remaining 75% over three years

Key Terms

Employee Stock Option, Vesting Commencement Date, derivative securities, underlying security

4 terms

Employee Stock Option financial

"security_title: "Employee Stock Option (Right to Buy)""

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

Vesting Commencement Date financial

"starting on April 15, 2026 (the "Vesting Commencement Date")"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

derivative securities financial

"transaction_type: "derivative" for the option grant"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

underlying security financial

"underlying_security_title: "Common Stock""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DETORE JAMES M.

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$67.68	04/15/2026		A		90,574		(1)	04/14/2036	Common Stock	90,574	$0	90,574	D

Explanation of Responses:

1. The stock option vests over a four-year period starting on April 15, 2026 (the "Vesting Commencement Date"), with 25% of the shares vesting on the date that is twelve months after the Vesting Commencement Date and the remainder vesting in thirty-six equal monthly installments over the subsequent three-year period.

	/s/ Joshua F. Patterson, Attorney-in-Fact for James DeTore	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did CGON’s CFO report in this Form 4 filing?

CG Oncology’s CFO, James M. Detore, reported receiving an option grant for 90,574 shares of common stock. This is a compensation-related stock option award, not an open-market stock purchase or sale, and reflects part of his long-term incentive package.

How many CGON shares are covered by the new stock option grant?

The stock option grant to CG Oncology’s CFO covers 90,574 shares of common stock. These are underlying shares that may be acquired in the future if the option is exercised, subject to the specified vesting schedule and the exercise price requirements.

What is the exercise price of the CGON CFO’s stock options?

The exercise price for the CFO’s stock options is $67.68 per share. This means he can purchase each underlying share at $67.68 once the options vest and are exercised, provided the options are still outstanding before their stated expiration date in 2036.

When do the CGON CFO’s options begin vesting and how is vesting structured?

The options begin vesting on April 15, 2026, the Vesting Commencement Date. Twenty-five percent of the shares vest 12 months afterward, and the remaining 75% vest in 36 equal monthly installments over the next three years, creating a four-year vesting period.

When do the CGON CFO’s stock options expire?

The CFO’s employee stock option grant expires on April 14, 2036. After that expiration date, any unexercised portion of the option can no longer be used to purchase CG Oncology common shares, even if vesting conditions had previously been satisfied.

Is this CGON Form 4 a stock purchase or sale by the CFO?

This Form 4 reflects a grant of employee stock options, not a stock purchase or sale. It is classified as an acquisition of derivative securities as compensation, with no open-market buying or selling of CG Oncology common stock reported in this particular filing.